Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer.

Takahiro Nozaki Ikuko Sakamoto Keiko Kagami Kenji Amemiya Yosuke Hirotsu Hitoshi Mochizuki Masao Omata

Published in: Journal of gynecologic oncology (2024)

We found that HRRm can be a useful biomarker for predicting the effects of PARP inhibitors in treating ovarian cancer and that the PFI can also be useful in recurrent ovarian cancer.

Keyphrases

dna damage
dna repair